HK Stock Market Move | REMEGEN (09995) rose more than 5%, and the results of the Phase III clinical study of Taetexinib for the treatment of systemic lupus erythematosus in China were published in NEJM.

REMEGEN (09995) rose more than 5%, as of press time, it rose 5.7% to HK $96.45, with a turnover of HK $2.05 billion. On the news front, according to the official WeChat account of REMEGEN, on October 16, REMEGEN announced that the results of the phase III clinical trial of Tabici for the treatment of systemic lupus erythematosus (SLE) in China were published in the top international medical journal "New England Journal of Medicine" (NEJM). It was reported that the trial met its primary endpoint, with a significant improvement in disease activity achieved in 67.1% of patients in the Tabici group compared to 32.7% in the placebo group. BLyS/APRIL dual-target biological agents have been confirmed as a transformative B cell therapy, highlighting the advantages of Tabici in the treatment of systemic lupus erythematosus. It is known that systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease that can affect multiple organs and lead to irreversible damage. More than half of patients will experience organ damage within 2-6 years of diagnosis. Despite the various treatment options available, including glucocorticoids, antimalarial drugs, immunosuppressants, and biological agents, many patients still face the challenge of disease activity, highlighting the urgent need for new therapies. Tabici was approved for the treatment of SLE in China in March 2021 and entered the national medical insurance drug list at the end of the same year, making it the world's first dual-target biological new drug for the treatment of SLE.